Cerus Corporation (NASDAQ:CERS)’s share price rose 8.5% during mid-day trading on Friday . The company traded as high as $2.57 and last traded at $2.55, with a volume of 1,787,514 shares changing hands. The stock had previously closed at $2.35.

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $7.00 target price on shares of Cerus Corporation in a report on Wednesday, June 7th. ValuEngine lowered shares of Cerus Corporation from a “sell” rating to a “strong sell” rating in a report on Saturday, June 17th. Zacks Investment Research raised shares of Cerus Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. BTIG Research reaffirmed a “buy” rating and issued a $5.00 target price on shares of Cerus Corporation in a report on Sunday, May 28th. Finally, BidaskClub lowered shares of Cerus Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $7.25.

The firm has a 50 day moving average of $2.38 and a 200-day moving average of $3.18. The stock’s market cap is $278.30 million.

Cerus Corporation (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.16). The business had revenue of $9.53 million during the quarter, compared to the consensus estimate of $9.14 million. Cerus Corporation had a negative return on equity of 120.31% and a negative net margin of 164.39%. Cerus Corporation’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.18) earnings per share. On average, equities research analysts expect that Cerus Corporation will post ($0.68) earnings per share for the current year.

In related news, insider Laurence M. Corash purchased 92,796 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was acquired at an average price of $2.45 per share, with a total value of $227,350.20. Following the completion of the purchase, the insider now directly owns 1,375,711 shares in the company, valued at $3,370,491.95. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.40% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Teachers Advisors LLC increased its position in Cerus Corporation by 0.4% in the fourth quarter. Teachers Advisors LLC now owns 269,964 shares of the biotechnology company’s stock worth $1,174,000 after buying an additional 1,152 shares during the period. Stephens Inc. AR increased its position in Cerus Corporation by 0.3% in the first quarter. Stephens Inc. AR now owns 950,729 shares of the biotechnology company’s stock worth $4,231,000 after buying an additional 2,539 shares during the period. American International Group Inc. increased its position in Cerus Corporation by 7.1% in the first quarter. American International Group Inc. now owns 62,374 shares of the biotechnology company’s stock worth $278,000 after buying an additional 4,127 shares during the period. The Manufacturers Life Insurance Company increased its position in Cerus Corporation by 5.6% in the second quarter. The Manufacturers Life Insurance Company now owns 87,994 shares of the biotechnology company’s stock worth $221,000 after buying an additional 4,688 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its position in Cerus Corporation by 7.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 81,132 shares of the biotechnology company’s stock worth $361,000 after buying an additional 5,920 shares during the period. 58.74% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Cerus Corporation (CERS) Stock Price Up 8.5%” was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/03/cerus-corporation-cers-stock-price-up-8-5.html.

Cerus Corporation Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.